ID | 62503 |
フルテキストURL | |
著者 |
Watari, Shogo
Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Araki, Motoo
Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
ORCID
Kaken ID
publons
researchmap
Matsumoto, Jun
Department of Personalized Medicine and Preventive Healthcare Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
ORCID
Kaken ID
researchmap
Yoshinaga, Kasumi
Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Sekito, Takanori
Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Maruyama, Yuki
Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Mitsui, Yosuke
Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Sadahira, Takuya
Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Kubota, Risa
Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Nishimura, Shingo
Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Wada, Koichiro
Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Kobayashi, Yasuyuki
Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Takeuchi, Hidemi
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
Tanabe, Katsuyuki
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
Kitagawa, Masashi
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
Morinaga, Hiroshi
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
Kitamura, Shinji
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
Sugiyama, Hitoshi
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
Ariyoshi, Noritaka
Department of Personalized Medicine and Preventive Healthcare Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Wada, Jun
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
Watanabe, Masami
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
Watanabe, Toyohiko
Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Nasu, Yasutomo
Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
|
抄録 | We evaluated the impact of vonoprazan on blood concentrations of tacrolimus via a retrospective analysis of 52 renal transplant recipients who took tacrolimus and converted from rabeprazole to vonoprazan between August 2018 and September 2019. We compared tacrolimus trough levels upon conversion among groups that were classified based on cytochrome P450 (CYP) gene polymorphisms. CYP3A5 groups were heterozygous or homozygous for CYP3A5∗1 and CYP3A5∗3 alleles. CYP2C19 genotypes were classified as extensive (∗1/∗1), intermediate (∗1/∗2 and ∗1/∗3) or poor metabolizers (∗2/∗2, ∗2/∗3 and ∗3/∗3). Tacrolimus trough levels increased only 0.3 ng/mL upon conversion in the CYP3A5∗3/∗3 group: 5.8 [3.4-7.2] vs 6.1 [3.8-7.9]; p = 0.06. No statistically significance changes in tacrolimus levels also occurred in the CYP3A5∗1/∗1 or CYP3A5∗1/∗3 groups. Subgroup analyses of CYP3A5∗3/∗3 demonstrated low changes for all three CYP2C19 subgroups: 5.2 [4.3-6.5] vs 6.2 [4.3-7.9]; p = 0.07, 6.1 [3.4-7.2] vs 6.7 [4.6-7.9]; p = 0.12 and 5.4 [3.6-6.5] vs 4.7 [3.8-6.3]; p = 1.00, respectively. Conversion to vonoprazan thus resulted in little increase of tacrolimus trough levels, even in the group predicted to be most susceptible (CYP3A5∗3/∗3 and 2C19∗1/∗1), thus supporting the safety of concomitant use of vonoprazan with tacrolimus.
|
キーワード | Cytochrome P450
tacrolimus
renal transplantation
CYP2C19
vonoprazan
rabeprazole
|
備考 | © 2021 The Japanese Society for the Study of Xenobiotics. This manuscript version is made available under the CC-BY-NC-ND 4.0 License.http://creativecommons.org/licenses/by-nc-nd/4.0/.This is the accepted manuscript version. The formal published version is available at [https://doi.org/10.1016/j.dmpk.2021.100407] .
|
発行日 | 2021-10-31
|
出版物タイトル |
Drug Metabolism and Pharmacokinetics
|
巻 | 40巻
|
出版者 | Elsevier Ltd.
|
開始ページ | 100407
|
ISSN | 13474367
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
OAI-PMH Set |
岡山大学
|
著作権者 | © 2021 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.
|
論文のバージョン | author
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
関連URL | isVersionOf https://doi.org/10.1016/j.dmpk.2021.100407
|
ライセンス | http://creativecommons.org/licenses/by-nc-nd/4.0/.
|
Citation | Shogo Watari, Motoo Araki, Jun Matsumoto, Kasumi Yoshinaga, Takanori Sekito, Yuki Maruyama, Yosuke Mitsui, Takuya Sadahira, Risa Kubota, Shingo Nishimura, Koichiro Wada, Yasuyuki Kobayashi, Hidemi Takeuchi, Katsuyuki Tanabe, Masashi Kitagawa, Hiroshi Morinaga, Shinji Kitamura, Hitoshi Sugiyama, Noritaka Ariyoshi, Jun Wada, Masami Watanabe, Toyohiko Watanabe, Yasutomo Nasu, Blood concentrations of tacrolimus upon conversion from rabeprazole to vonoprazan in renal transplant recipients: Correlation with cytochrome P450 gene polymorphisms, Drug Metabolism and Pharmacokinetics, Volume 40, 2021, 100407, https://doi.org/10.1016/j.dmpk.2021.100407.
|
オープンアクセス(出版社) |
非OA
|
オープンアーカイブ(出版社) |
非OpenArchive
|